Article Details
Retrieved on: 2025-01-17 16:56:18
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article details the Massachusetts biopharma's 2024 recovery, highlighting increased venture capital, IPOs, and M&A activity. Relating to corporate finance and entrepreneurship, it mentions involvement from private equity, like Vertex Pharmaceuticals, and compares Boston's industry to Cambridge and other states.
Article found on: www.massbio.org
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here